Ruxolitinib in Thrombocythemia and Polycythemia Vera
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This research is being done to see if the drug ruxolitinib is effective in reducing the
symptoms caused by low-risk essential thrombocythemia (ET) and polycythemia vera (PV).
- This research study involves the study drug Ruxolitinib.